公开(公告)号：US20190134036A1

公开(公告)日：2019-05-09

申请号：US16239719

申请日：2019-01-04

Applicant: Dermavant Sciences GmbH ,  Eisai R&D Management Co., Ltd.

Inventor： Ambrish VYAS ,  Seiji TAKEMOTO ,  Yoshihiro AKIMOTO

IPC: A61K31/517 ,  A61K47/06 ,  A61K9/00 ,  A61P17/06 ,  A61K47/14

CPC classification number: A61K31/517 ,  A61K9/0014 ,  A61K47/06 ,  A61K47/10 ,  A61K47/14 ,  A61P17/06

Abstract: Embodiments herein are directed to topical formulations of a compound represented by the formula (I), salt, metabolite, prodrug, or hydrate thereof along with a solvent, and a base. The compound is a PDE4 inhibitor and the topical formulations may be used to treat dermatological conditions such as, but not limited to, atopic dermatitis, seborrheic dermatitis, alopecia, contact dermatitis, psoriasis, urticaria, eczema, burns, sunburn, pancreatitis, hepatitis, lichen planus, scleritis, scleroderma, dermatomyositis, itching associated with any of the preceding conditions or a combination thereof.

公开(公告)号：US20240050462A1

公开(公告)日：2024-02-15

申请号：US17768283

申请日：2020-12-24

Applicant: Eisai R&D Management Co., Ltd.

Inventor： Seiji TAKEMOTO ,  Shuntaro ARASE ,  Yuta SUZUKI

IPC: A61K31/713 ,  A61K9/107 ,  A61K9/127 ,  A61P13/02

CPC classification number: A61K31/713 ,  A61K9/107 ,  A61K9/1272 ,  A61P13/02

Abstract: Disclosed is a pharmaceutical composition comprising a lipid complex, wherein the lipid complex comprises a double-stranded ribonucleic acid comprising a sense strand consisting of a nucleotide sequence set forth in SEQ ID NO: 145 and an antisense strand consisting of a nucleotide sequence set forth in SEQ ID NO: 146, and a pH of a solution of the lipid complex is 5.0 or less, or 7.5 or more.

公开(公告)号：US20170348311A1

公开(公告)日：2017-12-07

申请号：US15616405

申请日：2017-06-07

Applicant: Dermavant Sciences GmbH ,  Eisai R&D Management Co., Ltd.

Inventor： Ambrish VYAS ,  Seiji TAKEMOTO ,  Yoshihiro AKIMOTO

IPC: A61K31/517 ,  A61K47/10 ,  A61K47/06 ,  A61K47/14 ,  A61K9/00

CPC classification number: A61K31/517 ,  A61K9/0014 ,  A61K47/06 ,  A61K47/10 ,  A61K47/14 ,  A61P17/06

Abstract: Embodiments herein are directed to topical formulations of a compound represented by the formula (I), salt, metabolite, prodrug, or hydrate thereof along with a solvent, and a base. The compound is a PDE4 inhibitor and the topical formulations may be used to treat dermatological conditions such as, but not limited to, atopic dermatitis, seborrheic dermatitis, alopecia, contact dermatitis, psoriasis, urticaria, eczema, burns, sunburn, pancreatitis, hepatitis, lichen planus, scleritis, scleroderma, dermatomyositis, itching associated with any of the preceding conditions or a combination thereof.